By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Asterias Biotherapeutics 

6300 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-456-3800 Fax: n/a



Company News
Asterias Biotherapeutics Reports Second Quarter Financial Results And Reviews Recent Clinical Progress And Corporate Developments 8/15/2017 7:49:36 AM
Asterias Biotherapeutics Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2 8/14/2017 8:27:27 AM
Asterias Biotherapeutics Enrolls First Patient in Final Cohort of SCiStar Clinical Trial 8/9/2017 10:45:22 AM
Asterias Biotherapeutics Opens Two Additional Clinical Sites For AST-OPC1 SCiStar Study 8/3/2017 11:47:17 AM
Asterias Biotherapeutics To Report Second Quarter Results On August 14, 2017 7/31/2017 12:48:46 PM
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's AIS-A 20 Million Cell Cohort 7/17/2017 6:44:16 AM
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's Ais-B 10 Million Cell Cohort 7/12/2017 7:30:10 AM
Asterias Biotherapeutics Receives FDA Clearance To Enroll C-4 Patients In SCiStar Study 7/10/2017 6:25:24 AM
AIVITA Comments On Positive Findings From Asterias Biotherapeutics' SCiStar Trial For Spinal Cord Injury 6/14/2017 8:11:59 AM
Patients With Complete Paralysis Show Additional Recovery Of Arm, Hand And Finger Function At 9-Months After Treatment With Asterias Biotherapeutics' AST-OPC1 6/13/2017 7:28:06 AM